MDP:CC News and Press, Medexus Pharmaceuticals Inc. From 06/06/22

Study’s primary endpoint and key secondary endpoints were met Study found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm Study results accepted for publi...

Toronto Stock Exchange, Medexus Pharmaceuticals, The View From The C-Suite Canada NewsWire TORONTO , May 26, 2022 /CNW/ -  Ken D'Entremont, Chief Executive Officer, Medexus Pharmaceuticals (Medexus) (TSX: MDP) shares his Company's story in ...

TORONTO and CHICAGO, May 24, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic partner of Medexus, that medac received acknowledgement of receipt from the U.S. Food and Drug Administration ( FD...

Additional data collection and analysis reconfirms confidence in New Drug Application for Treosulfan NDA resubmission date consistent with previously announced timeline FDA decision still expected within six months of resubmission TORONTO and CHICAGO, April 22, 2022 (GLOBE NEWSW...

TORONTO and CHICAGO, April 19, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) will be presenting at the Bloom Burton & Co. Healthcare Investor Conference from May 2 to 3, 2022. The conference brings together U.S.,...